|
Nov 15
|
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova Brand
|
|
Jul 30
|
NovaBay Pharmaceuticals Reports Record Amazon Prime Day Sales
|
|
Jul 29
|
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
|
|
Jul 26
|
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
|
|
Jul 16
|
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
|
|
Jul 11
|
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
|
|
Jan 9
|
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
|
|
Dec 6
|
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
|
|
Nov 12
|
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023
|
|
Aug 8
|
NovaBay Pharmaceuticals to Hold Second Quarter 2023 Conference Call on August 10, 2023
|